Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Comparison of (211)At-PRIT and (211)At-RIT of Ovarian Microtumors in a Nude Mouse Model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Various functions of PBMC from colon cancer patients are not decreased compared to healthy blood donors.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Elin Cederkrantz
  • Eva Angenete
  • Tom Bäck
  • Peter Falk
  • Börje Haraldsson
  • Marie-Louise Ivarsson
  • Holger Jensen
  • Sture Lindegren
  • Ragnar Hultborn
  • Lars Jacobsson
Vis graf over relationer
The introduction of the short-lived α-emitter (211)At to intraperitoneal radioimmunotherapy has raised the issue of the tolerance dose of the peritoneum. The short range of the α-particles (70 μm) and the short half-life (7.21 h) of the nuclide yield a dose distribution in which the peritoneum is highly irradiated compared with other normal tissues. To address this issue, mice were injected with (211)At-trastuzumab to irradiate the peritoneum to absorbed doses ranging between 0 and 50 Gy and followed for up to 34 weeks. The peritoneum-to-plasma clearance of a small tracer, (51)Cr-ethylenediamine tetraacetic acid, was measured for evaluation of the small solute transport capacity of the peritoneal membrane. The macroscopic status of the peritoneum and the mesenteric windows was documented when the mice were sacrificed. Biopsies of the peritoneum were taken for morphology and immunohistochemical staining against plasminogen activator inhibitor-1 and calprotectin. Peritoneum-to-plasma clearance measurements indicated a dose-dependent decrease in peritoneal transport capacity in irradiated mice. However, macroscopic and microscopic evaluations of the peritoneal membrane showed no difference between irradiated mice versus controls. The results imply that the peritoneal membrane tolerates absorbed doses as high as 30-50 Gy from α-particle irradiation with limited response.
OriginalsprogEngelsk
TidsskriftCancer Biotherapy & Radiopharmaceuticals
Vol/bind27
Udgave nummer6
Sider (fra-til)353-64
Antal sider12
ISSN1084-9785
DOI
StatusUdgivet - 2012

ID: 36837471